Front Page Demo Slide


LATEST NEWS:   UCB faces U.S. patent challenge for epilepsy drug - BRUSSELS (Reuters) - The U.S. Patent and Trademark Office (PTO) is to review UCB's patent for its epilepsy drug Vimpat, the latest round in a legal battle between the Belgian pharmaceutical company and generic rivals.
LATEST NEWS:   GSK lung drug succeeds in big UK study, after earlier miss - LONDON (Reuters) - GlaxoSmithKline's new inhaled medicine Breo proved significantly better than standard care in a large British study that tested it in everyday use, providing a fillip for the product after the failure of another big trial in 2015.
LATEST NEWS:   U.S. e-cigarette use stalls as health concerns grow: Reuters/Ipsos poll - NEW YORK (Reuters) - Use of electronic cigarettes and other vaping devices has stalled in the United States as more Americans question their safety, according to a new online Reuters/Ipsos poll.
LATEST NEWS:   States on Zika's frontline see big gaps in funding, expertise - (Reuters) - In Mississippi, a small team of entomologists has begun the first survey of mosquito populations in decades. Experts do not believe the kind of mosquitoes most likely to carry the Zika virus are active in the state, but they cannot know for sure.
LATEST NEWS:   Patient can't always access complete medical records, doctors say - (Reuters Health) - Technology makes it possible for patients to access medical records online, but a thicket of legal issues may still keep people from always seeing everything in their chart, some doctors say.
LATEST NEWS:   Immediate aspirin after mini-stroke cuts risk of major stroke - (Reuters Health) - Starting treatment with aspirin right after a mini-stroke greatly reduces the risk of a major stroke in the following days, according to a new analysis.
LATEST NEWS:   Can ADHD appear for the first time in adulthood? - (Reuters Health) - Attention deficit hyperactivity disorder (ADHD), usually diagnosed in children, may show up for the first time in adulthood, two recent studies suggest.
LATEST NEWS:   Samsung Bioepis applies for approval to sell Remicade biosimilar in U.S. - SEOUL (Reuters) - South Korean biosimilars maker Samsung Bioepis Co Ltd said on Tuesday it has applied to the U.S. Food and Drug Administration (FDA) for approval to sell its version of blockbuster drug Remicade in the world's biggest healthcare market.
LATEST NEWS:   FDA staff question usefulness of Sanofi diabetes drugs - (Reuters) - A preliminary review by the U.S. Food and Drug Administration questioned the usefulness of a combination diabetes drug made by Sanofi SA's and said it was unclear whether one component, lixisenatide, contributed to its benefit.
LATEST NEWS:   France faults Bial and Biotrial over fatal drug trial - PARIS (Reuters) - Portuguese drugmaker Bial and French laboratory Biotrial are at fault "on several counts" for a failed drug trial that left one person dead and five others hospitalized in January, French Health Minister Marisol Touraine said on Monday.